119378-70-0

Usage

Uses

Used in Pharmaceutical Research:
(4-PHENYL-PIPERAZIN-1-YL)-ACETIC ACID X HCL is used as a research compound for the development of new medications. Its unique structure and properties make it a promising candidate for the synthesis of pharmaceuticals with potential therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (4-PHENYL-PIPERAZIN-1-YL)-ACETIC ACID X HCL is used as a building block for the synthesis of various drug candidates. Its versatile chemical properties allow for the creation of novel compounds with potential therapeutic effects.
Used in Drug Development:
(4-PHENYL-PIPERAZIN-1-YL)-ACETIC ACID X HCL is employed in the drug development process as a potential active pharmaceutical ingredient (API). Its unique structure and properties may contribute to the discovery of new drugs with improved efficacy and safety profiles.
Used in Biochemical Research:
In biochemical research, (4-PHENYL-PIPERAZIN-1-YL)-ACETIC ACID X HCL is used as a tool compound to study the interactions between biological molecules and potential drug targets. Its unique chemical properties enable researchers to gain insights into the mechanisms of action of various biological processes and diseases.
Used in Chemical Synthesis:
(4-PHENYL-PIPERAZIN-1-YL)-ACETIC ACID X HCL is utilized in chemical synthesis for the preparation of various organic compounds and pharmaceutical intermediates. Its versatile reactivity and functional groups make it a valuable building block in the synthesis of complex organic molecules.

InChI:InChI=1/C12H16N2O2.ClH/c15-12(16)10-13-6-8-14(9-7-13)11-4-2-1-3-5-11;/h1-5H,6-10H2,(H,15,16);1H

Upstream product

• 56968-26-4 ethyl 2-(4-phenyl-piperarazin-1-yl)acetate 
• 92-54-6 4-phenyl-1-piperazine 

Downstream Products

• 125762-96-1 (4-Phenyl-piperazin-1-yl)-acetic acid (2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-2-ylmethyl ester 
• 170567-84-7 1-t-butoxycarbonylamino-3-(1H-indol-3-yl)-2-[N-(2-((4-phenyl)piperazin-1-yl)acetyl)amino]propane 

Relevant academic research and scientific papers

Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents

In this paper, a series of podophyllotoxin piperazine acetate ester derivatives were synthesized and investigated due to their antiproliferation activity on different human cancer cell lines. Among the congeners, C5 manifested prominent cytotoxicity towar

Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: Binding characterization at D2/D3 receptors and elucidation of a pharmacophore model

A series of structurally constrained analogues based on hybrid compounds containing octahydrobenzo[g or f]quinoline moieties were designed, synthesized, and characterized for their binding to dopamine D2 and D3 receptors expressed in HEK-293 cells. Among the newly developed constrained molecules, trans-octahydrobenzo[f]quinolin-7-ol (8) exhibited the highest affinity for D2 and D3 receptors, the (-)-isomer being the eutomer. Interestingly, this hybrid constrained version 8 showed significant affinity over the corresponding nonhybrid version 1 (representing a constrained version of the aminotetralin structure only) when assayed under same conditions (Ki of 49.1 and 14.9 nM for 8 vs 380 and 96.0 nM for 1 at D2 and D3, respectively). Similar results were found with other lead hybrid compounds, indicating a contribution of the piperazine moiety in the observed enhanced affinity. On the basis of the data of new lead constrained derivatives and other lead hybrid derivatives developed by us, a unique pharmacophore model was proposed consisting of three pharmacophoric centers, two with aromatic/hydrophobic and one with cationic features.

Oxadiazole and thiadiazole derivatives of dihydropyridine NPY antagonists

A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of oxadiazole, thiadiazole and thiadiazole oxide derivatives of dihydropyridines of Formula I. wherein B is with X being O, S or and X1 is O or S. As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.